Drug intelligence / Profile preview

68Ga NOTA anti-HER2 sdAb

Development stage: Unknown
Lead developer: Vrije Universiteit Brussel
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga NOTA anti-HER2 sdAb (also known as ABS-011 or ABSCINT-HER2) is an investigational radiopharmaceutical PET imaging tracer consisting of a single-domain antibody (sdAb, or Nanobody) designated 2Rs15d that targets Domain 1 of the human epidermal growth factor receptor 2 (HER2). The sdAb is conjugated to the bifunctional chelator NOTA and radiolabeled with the positron emitter Gallium-68 (68Ga). Developed as a non-invasive diagnostic tool, it enables same-day, whole-body PET/CT imaging to assess HER2 receptor expression and spatial heterogeneity across primary and metastatic lesions, including brain metastases, in patients with breast and gastric cancers. Originally developed by the Vrije Universiteit Brussel (VUB) and its spin-off Abscint, the global rights to the asset were acquired by Curium in August 2026. It is currently in Phase IIb clinical development.

Other names: 2Rs15d68Ga-NOTA-2Rs15d68Ga-NOTA-HER2-sdAb68Ga-NOTA-anti-HER2-sdAb[68Ga]Ga-NOTA-anti-HER2-sdAbABSCINT-HER2ABSCINT-HER-2ABSCINT-HER 2Ga-68-NOTA-anti-HER2-sdAbGa68-NOTA-anti-HER2-sdAbGa 68-NOTA-anti-HER2-sdAbgallium-68-labeled NOTA-anti-HER2-sdAbgallium68-labeled NOTA-anti-HER2-sdAbgallium 68-labeled NOTA-anti-HER2-sdAbgallium-68-labeled anti-HER2 single-domain antibodygallium68-labeled anti-HER2 single-domain antibodygallium 68-labeled anti-HER2 single-domain antibody

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on 68Ga NOTA anti-HER2 sdAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga NOTA anti-HER2 sdAb.

Explore the full profile